The article presents comments of the author on the study conducted by researcher G.L. Bakris and colleagues on the safety and efficacy of dual blockade of the renin-angiotensin aldosterone system by adding the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone to an angiotensinconverting enzyme (ACE) inhibitor in patients with diabetic nephropathy